For CFM, polymethylmethacrylate should not be used in filling procedures; measure comes into force on June 2
The CFM () banned on Friday (May 29, 2026) the medical use of PMMA (polymethylmethacrylate) as a filler for aesthetic and reparative procedures in Brazil. The measure comes into force on Tuesday (June 2, 2026), with the publication of Resolution No. 2,461 of 2026 in the DOU (Official Gazette of the Union) on the same date.
PMMA is a permanent and not absorbable by the body. It is used in products such as contact lenses, orthopedic cement and implants. In recent years, it has also been applied in aesthetic procedures for facial and body fillers.
The resolution maintains authorization only for the treatment of lipodystrophy in patients with HIV/AIDS, as long as it is carried out in highly complex units accredited by the SUS (Unified Health System) and in accordance with the protocols and guidelines of the Ministry of Health.
In a note released this Saturday (May 30, 2026), the SBCP (Brazilian Society of Plastic Surgery) declared support for the Council’s resolution.
According to SBCP, the measure follows guidance that was already being adopted internally. He stated in a note that he recommended that his associates avoid using PMMA “in any circumstances or quantity”given the risks associated with the material and the available scientific evidence. Read the document (PDF – 122 KB).
“Several scientific studies and national and international guidelines document serious complications that can arise months or years after its application”states the entity.
The restriction on PMMA gained strength after yet another case of death associated with the use of the substance. On Tuesday (May 26, 2026), Roseli Fernandes de Oliveira Romeiro Vieira, 48 years old, died after undergoing a procedure on the buttocks and the back of the thighs using the product.
Read the full CFM note:
“CFM prohibits the medical use of the substance in the country
“As of this Tuesday (02), the medical use of PMMA (polymethylmethacrylate) will be prohibited throughout Brazil as a filler substance, whether for aesthetic or reparative purposes. The only exception is for the treatment of lipodystrophy in patients with HIV/AIDS and as long as it is carried out in highly complex units accredited by the Unified Health System (SUS) and in accordance with the clinical protocols and therapeutic guidelines of the Ministry of Health. This is what Resolution no. 2,461/2026 of the Federal Council of Medicine (CFM), which will be published on June 2, 2026 in the Official Gazette of the Union (DOU).
